Tisento Therapeutics

🗓 Founded 2023👥 16 employees💰 Last funded May 2023
Biotechnology Research🌐 tisentotx.com
Website LinkedIn
Ti sento means “I hear you" in Italian. At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem, and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company. We are on a mission to deliver medicines that address what matters most. Our lead candidate is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator, which is advancing in MELAS and other genetic mitochondrial diseases. Zagociguat is ideally suited to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Tisento Therapeutics?
Tisento Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Tisento Therapeutics last raise funding?
The most recent investment in Tisento Therapeutics recorded on gritt.io was in May 2023.
When was Tisento Therapeutics founded?
Tisento Therapeutics was founded in 2023.
What industry is Tisento Therapeutics in?
Tisento Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.